See more : The Law Debenture Corporation p.l.c. (LWDB.L) Income Statement Analysis – Financial Results
Complete financial analysis of Theratechnologies Inc. (THTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Theratechnologies Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Taka-Q Co., Ltd. (8166.T) Income Statement Analysis – Financial Results
- Webster Financial Corporation (WBS-PG) Income Statement Analysis – Financial Results
- Rockland Resources Ltd. (RKL.CN) Income Statement Analysis – Financial Results
- Infrastrutture Wireless Italiane S.p.A. (0R8S.L) Income Statement Analysis – Financial Results
- Enapter AG (H2O.DE) Income Statement Analysis – Financial Results
Theratechnologies Inc. (THTX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.theratech.com
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 81.76M | 80.06M | 69.82M | 66.05M | 63.22M | 44.05M | 33.23M | 27.60M | 22.55M | 5.90M | 7.13M | 13.66M |
Cost of Revenue | 19.64M | 26.28M | 23.26M | 26.90M | 26.08M | 14.68M | 17.15M | 10.14M | 6.70M | 7.07M | 10.46M | 11.47M |
Gross Profit | 62.13M | 53.78M | 46.56M | 39.15M | 37.14M | 29.38M | 16.07M | 17.47M | 15.85M | -1.17M | -3.33M | 2.18M |
Gross Profit Ratio | 75.99% | 67.17% | 66.69% | 59.27% | 58.75% | 66.68% | 48.37% | 63.28% | 70.29% | -19.90% | -46.72% | 15.99% |
Research & Development | 30.37M | 36.94M | 28.27M | 18.02M | 10.84M | 7.77M | 9.19M | 5.65M | 4.11M | 4.95M | 7.09M | 7.08M |
General & Administrative | 15.62M | 17.36M | 14.62M | 12.23M | 8.33M | 5.83M | 4.51M | 3.57M | 2.99M | 4.00M | 3.55M | 5.50M |
Selling & Marketing | 26.77M | 39.39M | 28.91M | 26.86M | 26.48M | 21.69M | 20.17M | 10.86M | 9.66M | 6.10M | 236.05K | 857.67K |
SG&A | 42.39M | 56.75M | 43.53M | 39.09M | 34.81M | 25.02M | 24.67M | 14.54M | 12.74M | 10.10M | 3.84M | 6.36M |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 850.00K | 22.07M |
Operating Expenses | 72.76M | 93.69M | 71.80M | 57.11M | 45.65M | 32.79M | -30.64M | -16.76M | -14.28M | -8.21M | -901.69K | -16.97M |
Cost & Expenses | 92.39M | 119.97M | 95.06M | 84.01M | 71.73M | 47.47M | -13.48M | -6.63M | -7.58M | -1.14M | 9.56M | -5.50M |
Interest Income | 0.00 | 316.00K | 195.00K | 299.00K | 1.10M | 285.00K | 261.99K | 77.44K | 30.76K | 173.52K | 429.60K | 762.04K |
Interest Expense | 10.55M | 6.50M | 5.66M | 5.36M | 4.99M | 2.53M | 1.07M | 1.44M | 1.87M | 1.05M | 12.25K | 23.12K |
Depreciation & Amortization | 3.30M | 12.03M | 8.58M | 8.84M | 7.50M | 4.14M | 1.55M | 1.57M | 1.44M | 1.00M | 114.25K | 567.75K |
EBITDA | -10.31M | -27.87M | -17.16M | -9.18M | 28.01K | 731.32K | -11.68M | 3.79M | 4.55M | -6.68M | -7.06M | -3.60M |
EBITDA Ratio | -12.61% | -33.92% | -23.38% | -13.89% | 0.06% | 1.66% | -21.24% | 16.31% | 20.17% | -113.15% | -98.94% | -26.39% |
Operating Income | -10.63M | -39.91M | -25.24M | -17.96M | -8.51M | -3.41M | -8.60M | 2.93M | 3.11M | -7.68M | -7.17M | -4.17M |
Operating Income Ratio | -13.00% | -49.85% | -36.14% | -27.19% | -13.47% | -7.75% | -25.89% | 10.62% | 13.79% | -130.11% | -100.54% | -30.54% |
Total Other Income/Expenses | -12.91M | -6.89M | -6.43M | -4.69M | -3.98M | -2.56M | -5.72M | -2.15M | -1.50M | -1.53M | 3.37M | -9.86M |
Income Before Tax | -23.54M | -46.79M | -31.66M | -22.65M | -12.50M | -5.77M | -14.30M | 781.10K | 1.61M | -9.21M | -3.80M | -14.03M |
Income Before Tax Ratio | -28.79% | -58.45% | -45.35% | -34.29% | -19.77% | -13.11% | -43.04% | 2.83% | 7.12% | -156.12% | -53.34% | -102.71% |
Income Tax Expense | 421.00K | 443.00K | 63.00K | 16.00K | 4.99M | -1.25M | -2.17K | 475.81K | 426.91K | 27.17K | 24.55K | 5.03K |
Net Income | -23.96M | -47.24M | -31.73M | -22.67M | -12.50M | -4.52M | -14.30M | 305.29K | 1.18M | -9.24M | -3.83M | -14.03M |
Net Income Ratio | -29.30% | -59.00% | -45.44% | -34.32% | -19.77% | -10.27% | -43.04% | 1.11% | 5.23% | -156.58% | -53.69% | -102.75% |
EPS | -0.91 | -1.98 | -1.37 | -1.18 | -0.65 | -0.24 | -0.78 | 0.02 | 0.06 | -0.61 | -0.25 | -0.93 |
EPS Diluted | -0.91 | -1.98 | -1.37 | -1.18 | -0.65 | -0.24 | -0.78 | 0.02 | 0.07 | -0.61 | -0.25 | -0.92 |
Weighted Avg Shares Out | 26.33M | 23.81M | 23.09M | 19.25M | 19.23M | 18.99M | 18.37M | 16.45M | 19.64M | 15.25M | 15.25M | 15.15M |
Weighted Avg Shares Out (Dil) | 26.33M | 23.81M | 23.09M | 19.25M | 19.23M | 18.99M | 18.37M | 16.65M | 15.79M | 15.25M | 15.25M | 15.25M |
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
Theratechnologies to Present at Upcoming Investor Conferences in September
Why Fast-paced Mover Theratechnologies (THTX) Is a Great Choice for Value Investors
Despite Fast-paced Momentum, Theratechnologies (THTX) Is Still a Bargain Stock
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
Theratechnologies (THTX) Is Attractively Priced Despite Fast-paced Momentum
Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Theratechnologies Reports on its Annual Meeting of Shareholders
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
Source: https://incomestatements.info
Category: Stock Reports